RAPH (Raphael Pharmaceutical) Research & Development: $0.60 Mil (TTM As of Mar. 2026)


RAPH Raphael Pharmaceutical Inc RAPH
37 GF Score
Price $1.40
! 2 Warning Signs
View Full Analysis

What is Raphael Pharmaceutical Research & Development?

Raphael Pharmaceutical RAPH 37 Research & Development is $0.60 Mil as of Mar. 2026. GuruFocus rates RAPH with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Raphael Pharmaceutical's Research & Development for the three months ended in Mar. 2026 was $0.04 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.60 Mil.

Raphael Pharmaceutical  (OTCPK:RAPH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Raphael Pharmaceutical Research & Development Related Terms

Raphael Pharmaceutical Research & Development Historical Data

* Premium members only.

The historical data trend for Raphael Pharmaceutical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raphael Pharmaceutical Research & Development Chart

Raphael Pharmaceutical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.78 1.18 0.57 0.78 0.63

Raphael Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.14 0.07 0.35 0.04
RAPH
37GF Score
Raphael Pharmaceutical Inc RAPH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Raphael Pharmaceutical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.60 Mil mean?
Raphael Pharmaceutical (RAPH) has a Research & Development of $0.60 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Raphael Pharmaceutical and its competitors.
Is Raphael Pharmaceutical's Research & Development too high?
Raphael Pharmaceutical's current Research & Development is $0.60 Mil. Overall, Raphael Pharmaceutical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Raphael Pharmaceutical's Research & Development compare to TXMD and AYTU?
Raphael Pharmaceutical's Research & Development of $0.60 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Raphael Pharmaceutical and its competitors. Raphael Pharmaceutical's current Research & Development is $0.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raphael Pharmaceutical stock overvalued right now?
Raphael Pharmaceutical (RAPH) has a current Research & Development of $0.60 Mil. The current Research & Development is $0.60 Mil. Raphael Pharmaceutical's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Raphael Pharmaceutical (RAPH), the current Research & Development is $0.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Raphael Pharmaceutical Business Description

Address 4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605
Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil. Its product is RaphaWell, which includes CBG and Sesame Oil Supplement.
37GF Score

Get the complete analysis for RAPH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price